Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

DSpace Repository

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Author: Mavratzas, A.; Baek, S.; Gerber, B.; Schmidt, M.; Moebus, V; Foerster, F.; Grischke, E. M.; Fasching, P.; Strumberg, D.; Solomayer, E.; Klare, P.; Windemuth-Kieselbach, C.; Hartmann, S.; Schneeweiss, A.; Marine, F.
Tübinger Autor(en):
Grischke, Eva-Maria
Published in: Breast (2019), Bd. 45, S. 22-28
Verlagsangabe: Churchill Livingstone
Language: English
Full text: http://dx.doi.org/10.1016/j.breast.2019.02.002
ISSN: 1532-3080
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)